SCHEMBL7185140

SCHEMBL7185140

CCOC(=O)c1cn(-c2cccc([N+](=O)[O-])c2)c2ncccc2c1=O

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 11/20 0.51
KCNH2 Q12809 8/20 0.51
NPC1 O15118 1/20 0.50
PDE4B Q07343 2/20 0.49
PDE4D Q08499 2/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.48
ELANE P08246 1/20 0.46
KMT2A Q03164 2/20 0.46
SLC5A1 P13866 1/20 0.45
SLC5A2 P31639 1/20 0.45
PDE4C Q08493 1/20 0.45
MEN1 O00255 1/20 0.44
ALOX12 P18054 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8247255 0.86 ELANE (0.58) PDE4AKCNH2PDE4BPDE4DELANE
SCHEMBL7168075 0.85 PDE4A (0.56) PDE4AKCNH2PDE4BPDE4DPDE4C
SCHEMBL8437043 0.84 PDE4A (0.54) PDE4AKCNH2PDE4BPDE4DELANE
SCHEMBL28255065 0.84 NPC1 (0.58) PDE4ANPC1PDE4BPDE4DALDH1A1
SCHEMBL1565419 0.84 PDE4A (0.70) PDE4AKCNH2NPC1LMNAMAPT
SCHEMBL7185413 0.84 PDE4A (0.65) PDE4AKCNH2ALDH1A1ELANE
SCHEMBL7185969 0.83 PDE4A (0.62) PDE4AKCNH2LMNAELANE
SCHEMBL8237731 0.83 PDE4A (0.53) PDE4AKCNH2PDE4BPDE4DELANE
SCHEMBL6395629 0.82 ELANE (0.61) PDE4AKCNH2PDE4BPDE4DELANE
SCHEMBL1565338 0.82 KCNH2 (0.52) PDE4AKCNH2PDE4BPDE4DELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541480-B2 Controlling cytokines SUNTORY LIMITED (JP) 2003-04-01 US disclosed
US-20020006935-A1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor DAIICHI ASUBIO PHARMA CO., LTD. (JP) 2002-01-17 US disclosed
US-6297248-B1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor SUNTORY LIMITED (JP) 2001-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006935-A1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor PDE3A, PDE5A, PDE3B PDE4A 4/4885KCNH2 559/4885NPC1 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.